Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Future Projections in Thyroid Eye Disease
source: The Journal of Clinical Endocrinology & Metabolism
year: 2022
authors: Giuseppe Barbesino, Mario Salvi, Suzanne K Freitag
summary/abstract:Background and aims: This review aims to summarize current and emerging therapies for treatment of thyroid eye disease (TED), in the light of novel understanding of pathogenetic mechanisms, leading to new treatment options and clinical trials.
Methods: We reviewed and analyzed peer-reviewed literature reporting recent translational studies and clinical trials in the treatment of TED. Searches were made at www.pubmed.gov with keywords “thyroid eye disease,” “Graves’ ophthalmopathy,” “thyroid orbitopathy,” and “Graves’ orbitopathy.”
Results: Surgery is reserved for rehabilitation in chronic TED or for emergent compressive optic neuropathy. Oral and intravenous glucocorticoid therapy has been used for decades with variable efficacy in acute TED, but results may be temporary and side effects significant. Nonsteroidal oral immunosuppressive agents offer modest benefit in TED. Several immunomodulatory monoclonal antibodies, including rituximab and tocilizumab, have shown efficacy for inactivating TED. Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, clinical activity score, diplopia, and quality of life in patients with active TED, with good tolerability. Newly proposed TED therapies, currently in preclinical and clinical trial phases, include thyroid-stimulating hormone (TSH) receptor inhibitory drugs, RVT-1401, local anti-vascular endothelial growth factor therapy, IGF-1R drugs delivered subcutaneously and orally, and desensitization to the TSH receptor with modified TSH receptor peptides.
Conclusion: New, albeit incomplete, understanding of the molecular mechanisms of TED has led to new promising therapies and offered improved outcomes in TED patients. Their full role and their relationship to classical immune suppression should be clarified over the next few years.
organization: Harvard Medical School, USA; Ospedale Maggiore Policlinico, ItalyDOI: 10.1210/clinem/dgac252
read more full text
myBinderRelated Content
-
Geeta Lal, MDDr. Lal is Associate Professor of Surger...
-
What Is Thyroid Eye Disease (TED)?https://www.youtube.com/watch?v=OVUZcQWF...
-
Antithyroid Drugs (Beyond the Basics)Antithyroid drugs have several benefits ...
-
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye DiseaseContext: Thyroid eye disease (TED), a v...
-
Ashley Anderson Campbell, MDAshley A. Campbell is an Assistant Profe...
-
David Schneider, MD, MS, FACSDr. Schneider is certified by the Americ...
-
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth DriversHorizon Therapeutics plc announced today...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google